Author

Jane Gaylard

Observed names: Gaylard, Jane, J Gaylard, J. Gaylard, Jane Gaylard (16242410)

Observed institutions: Brighton and Sussex Medical School, University of Siena, University of Sussex, University of Dundee, Royal Surrey County Hospital, Royal Shrewsbury Hospital, Princess Royal Hospital, London School of Hygiene & Tropical Medicine, Alexandra Hospital, Renewable Energy Alaska Project, Azienda Ospedaliera Universitaria Senese, Shrewsbury and Telford Hospital NHS Trust, University Hospitals Sussex NHS Foundation Trust, Barnsley Hospital, Brighton and Sussex University Hospitals NHS Trust, RESTART, Canadian Critical Care Trials Group, University of Brighton, Medical Research Council

OpenAlex ID: A5062928728

Mapping the human genetic architecture of COVID-19

2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Whole-genome sequencing reveals host factors underlying critical COVID-19

2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 326

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

2018 · Martin Dennis, Gillian Mead, et al. · The Lancet · 287

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

2021 · Hesham Abdelhady, Marwa Abdelrazik, et al. · JAMA · 210

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

2019 · Rustam Al-Shahi Salman, MS Dennis, et al. · The Lancet · 199

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

2017 · Philip M Bath, Lisa J Woodhouse, et al. · The Lancet · 181

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 146

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 136

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

A second update on mapping the human genetic architecture of COVID-19

2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

2021 · Yaseen M. Arabi, Anthony C. Gordon, et al. · Intensive Care Medicine · 99

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

2019 · Rustam Al-Shahi Salman, David P Minks, et al. · The Lancet Neurology · 94

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

2023 · Simin Florescu, Delia Stanciu, et al. · JAMA · 63

Intravenous Vitamin C for Patients Hospitalized With COVID-19

2023 · The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Simin Florescu, et al. · JAMA · 53

Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage

2021 · Rustam Al-Shahi Salman, Martin S. Dennis, et al. · JAMA Neurology · 50

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

2021 · Chiara Fallerini, Nicola Picchiotti, et al. · Human Genetics · 37

What Factors Determine Treatment Outcome in Aneurysmal Subarachnoid Hemorrhage in the Modern Era? A Post Hoc STASH Analysis

2017 · Mario Teo, Mathew R. Guilfoyle, et al. · World Neurosurgery · 24

Works count: 43

Citation count: 5,778

H-index: 25

I10-index: 30